The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
JUST LOOK AT THIS BEFORE INVESTING https://www.youtube.com/watch?v=hL3MSfuV91A https://www.youtube.com/watch?v=lDy-DcENBUA https://www.youtube.com/watch?v=XMxL-Em9Pg8 ME BOB looking good i am in ps coking price up profits up
Director Deals - Be Heard Group PLC (BHRD) Radhi Goss-Custard, Non Executive Director, 178,571 shares in the company on the 29th November 2017 at a price of 2.80p. The Director now holds 764,325 shares. Story provided by StockMarketWire.com Director deals... 29 November 2017 15:50 Director Deals - Be Heard Group PLC (BHRD) Robin Price, Financial Director, 357,142 shares in the company on the 29th November 2017 at a price of 2.80p. The Director now holds 2,897,227 shares. Story provided by StockMarketWire.com Director deals data... 29 November 2017 15:50 Director Deals - Be Heard Group PLC (BHRD) Ian Maude, Executive Director, 178,571 shares in the company on the 29th November 2017 at a price of 2.80p. The Director now holds 2,605,989 shares. Story provided by StockMarketWire.com Director deals data... 29 November 2017 15:50 Director Deals - Be Heard Group PLC (BHRD) David Wilkinson, Non Executive Director, 535,714 shares in the company on the 29th November 2017 at a price of 2.80p. The Director now holds 1,886,208 shares. Story provided by StockMarketWire.com Director deals... 29 November 2017 15:50 Director Deals - Be Heard Group PLC (BHRD) David Morrison, Non Executive Director, 2,142,857 shares in the company on the 29th November 2017 at a price of 2.80p. The Director now holds 2,142,857 shares. Story provided by StockMarketWire.com Director deals... 29 November 2017 15:50 ME BOB with all these directors buying Wednesday 29th surely they can see something we can't , so i am in for the ride good luck
November 10 2017 BE HEARD GROUP RAISES �6.2MLN AS IT BUYS LONDON BASED CREATIVE AGENCY, THE CORNER NEWSWIRE October 18 2017 LONDON TAXI FIRM ADDISON LEE JUMPS IN WITH BE HEARD BIG PICTURE September 11 2017 BE HEARD GROUP JOINING THE DOTS NEWSWIRE September 11 2017 BE HEARD "HAS ENCOURAGING MOMENTUM", NUMIS SECURITIES SAYS NEWSWIRE August 25 2017 BE HEARD CHANGE TO MMT EARN-OUT WILL BENEFIT BOTH SIDES VIDEO August 04 2017 BE HEARD SOUNDING GOOD TO INVESTORS NEWSWIRE August 03 2017 BE HEARD HAILS RAPID DELIVERY OF MICROSITE FOR VODAFONE UK NEWSWIRE August 02 2017 BE HEARD CONFIDENT OF FULL-YEAR OUTLOOK AFTER STRONG FIRST HALF VIDEO June 21 2017 'WE'RE IN A UNIQUE PLACE' - BE HEARD'S NEW GROWTH OFFICER RICHARD COSTA-D�SA NEWSWIRE June 16 2017 BE HEARD'S DIGITAL AGENCY MMT COMES AWAY WITH MORE AWA
Trade Date Action Notifier Price Currency Amount Holding 29-Nov-17 Placing Trade Notifier Information for Be Heard Group Peter Scott 2.8 GBX 2,678,571 19856680 29-Nov-17 Placing Trade Notifier Information for Be Heard Group David Morrison 2.8 GBX 2,142,857 2142857 29-Nov-17 Placing Trade Notifier Information for Be Heard Group David J. Poutney 2.8 GBX 3,892,857 10692857 29-Nov-17 Placing Trade Notifier Information for Be Heard Group David Wilkinson 2.8 GBX 535,714 1886208 29-Nov-17 Placing Trade Notifier Information for Be Heard Group Ian Maude 2.8 GBX 178,571 2605989 29-Nov-17 Placing Trade Notifier Information for Be Heard Group Rakhi Parekh 2.8 GBX 178,571 764325 29-Nov-17 Placing Trade Notifier Information for Be Heard Group Robin Price 2.8 GBX 357,142 2897227
So hear we have a company with 1. �31 billion order book 2. full years results inline with expectations and beyond. 3.P/E around 8.81 4.a dividend yield of over 4% and rising ,as it has done since 2000 5.essential service work in UK defence isolated from any budget pressures. 6.last half year results robust, revenue rose 5.9% 7. a well run company in general me bob i scratch my head and disbelieve the sp
Despite generating most of its revenues from the UK, unlike Ultra Electronics, Babcock�s operating performance does not appear to be suffering from the funding pressure on the Ministry of Defence. The group noted that �the vast majority of the work we do is critical and therefore not discretionary, and the group�s performance over the last decade would suggest the essential services we provide in defence and in emergency services are to a significant extent insulated against any budgetary pressures.�
Outlook Despite the volatile background, we continue to see opportunities across all our markets in both the UK and internationally. We are intent on delivering value to our shareholders through a focus on margins, returns and cash flow. Our c�31 billion order book and pipeline provides excellent revenue visibility and underpins our expectations for continued growth. The Board continues to expect full year results to be in line with expectations and we remain confident of making good progress this year and beyond.
https://www.***************************/babcock-international-group-plc-94-potential-upside-indicated-by-jp-morgan-cazenove/412740533
Shareholders Name Equities % Invesco Asset Management Ltd. 50,160,084 9.92% Standard Life Investments Ltd. 35,901,388 7.10% Capital Research & Management Co. (World Investors) 29,261,855 5.79% Woodford Investment Management Ltd. 25,474,689 5.04% Capital Research & Management Co. (Global Investors) 18,422,798 3.64% Legal & General Investment Management Ltd. 14,352,920 2.84% Ignis Investment Services Ltd. 9,860,240 1.95% M&G Investment Management Ltd. 8,769,851 1.73% BlackRock Advisors (UK) Ltd. 8,119,670 1.61% UBS Asset Management (UK) Ltd. 7,977,000 1.58% ME BOB. and they all probable bought in at a lot higher than the price is now long term a good investment , over sold in my opinion . ex-div DECEMBER, bought some more today , g luck
Emma Walmsley confirmed an interest in Pfizer�s consumer unit and said it would be �would be irresponsible� to commit to dividend stability in the longer term. me, this type of statement only confirms she is waiting until 2018 as promised before cutting the dividend, it's on the cards, my guess is we may see the sp fall further in anticipation of the dividend cut how low it's going to go is anybody's guess , this should be no surprise to the market as at this very minute the share price is being adjusted in anticipation of a dividend cut in 2018 as we have seen a small rise today it's possible we are near the bottom, but i could be wrong.
What on earth's going on at GSK ,whereby the share price as devalued by around 14% in a month, The new CEO seems to me to lack experience by not putting a stop to this downward sp fall / crash by press release statement to share holders, explaining the companies intentions in 2018 my suggestion is if you need to raise money why not have a right's issue , only my guess but if they reduce the dividend as suggested, the sp could drop even further. at the moment the sp seems to be adjusted down in expectations of a dividend cut in 2018 , the problem is how much further is it going to fall .?????
It says that 89% of revenue is now confirmed for the year ending 31 March 2018. That ought to provide management with fairly good visibility of profits for this year. The shares now trade on a forecast P/E of 10, with a prospective yield of 3.6%. If Babcock can maintain its current level of performance, I believe the shares should offer good value at current levels.
It says that 89% of revenue is now confirmed for the year ending 31 March 2018. That ought to provide management with fairly good visibility of profits for this year. The shares now trade on a forecast P/E of 10, with a prospective yield of 3.6%. If Babcock can maintain its current level of performance, I believe the shares should offer good value at current levels.
To cut or not to cut� In my view, Glaxo will reduce its dividend yield. Maintaining the payout at 80p per share has really taken its toll on the business as net debt has risen from �9bn to �14bn over the past six years. Shareholder equity (total assets minus total liabilities) has collapsed from �8bn to �1.1bn over the same period. If this trend continues, and growth remains sluggish, sooner or later the company will have to make some tough decisions. I believe management should act before it is pushed. A 50% cut would reduce the payout to 40p per share, that�s still a yield of around 3% at current prices, which is only just below the market average. Yet it may be too low for some investors.
THE MAIN PROBLEMS GSK ARE FACING ARE 1.Trump bad mouthing parimutuels companies and vowing to reduce prices Donald Trump says drug companies are 'getting away with murder' and vows to reduce prices The President also claims that 'the world is taking advantage of us'� Alexandra Wilts�Washington DC� Monday 16 October 2017 21:01 BS 2.WILL GSK CUT THERE 6% DIVIDEND IN 2018 POS. TO 3% ? Is GlaxoSmithKline plc�s 6% dividend yield safe? Rupert Hargreaves�|�Sunday, 5th November, 2017�|�More on:�GSK Following the release of�GlaxoSmithKline�s�(LSE: GSK)third-quarter figures last week, shares in the company have crumbled due to rising concerns about the company�s dividend�payout.� This isn�t the first time the company has faced such concerns. Several years ago the shares took a beating as the City proclaimed that falling earnings per share, a result of patent expirations, would force the company to slash its shareholder distribution.� This cut never materialised. Instead, management promised to hold the payout at 80p per share until at least 2018.� Unfortunately, it�s now looking increasingly�likely that the firm will slash its payout next year.� Turning the business around� Over the past few years, Glaxo�s business has been through a rough patch. Luckily, the firm has been able to recover from its problems, and thanks to new treatments, as well as weak sterling, earnings have ticked higher. After earnings per share hit a low of 75p in 2015, this year the company is on track to earn 110p.� EPS of 110p easily cover the 80p per share dividend payout. However, on a cash basis, the payout looks vulnerable. Indeed, for the first nine months of this year, the company produced just over �4bn in cash from operations and spent �1.5bn on capex, giving a free cash flow of �2.5bn before dividends. Dividends for the period amounted to �3bn leaving a gap of �500m.� Going forward, the cash squeeze might get even tighter if the company chooses to pursue growth.�Glaxo is eyeing potential acquisitions from�Pfizer�in the US and�Merck�in Germany�to boost its consumer division.� The Pfizer business is estimated to be worth $14bn.� Meanwhile, the firm is apparently preparing to buy out the 36.5% stake in its joint venture with�Novartis�for $10.3bn. These are some sizable figures, and Glaxo�s balance sheet can�t take on much more debt to fund acquisitions. So, it�s entirely�reasonable to assume that the firm could cut its dividend by 50% or more to save a few billion a year and fund expansion.� This is a delicate trade-off. On the one hand, a dividend cut will help reignite earnings�growth. On the other hand, a re